The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension
Abstract
Background The application of iloprost, a stable prostacyclin analogue, by inhalation has been shown to improve hemodynamic variables in patients with primary pulmonary hypertension. However, repetitive inhalations are required due to its short-term effects. One potential approach to prolong and increase the vasorelaxant effects of aerosolized iloprost might be to combine use with phosphodiesterase inhibitors. Methods and Results The short-term effects of 8.4 to 10.5 μg of aerosolized iloprost, the phosphodiesterase type 5 inhibitor sildenafil, and the combination thereof were compared in 5 patients with primary pulmonary hypertension. Aerosolized iloprost resulted in a more pronounced decrease in mean pulmonary arterial pressure (PAP) than sildenafil alone (9.4±1.3 versus 6.4±1.1 mm Hg; P <0.05). The reduction in mean PAP after sildenafil was maximal after the first dose (25 mg). The combination of sildenafil plus iloprost lowered mean PAP significantly more than iloprost alone (13.8±1.4 versus 9.4±1.3 mm Hg; P <0.009). No significant changes in heart rate or systemic arterial pressure were observed during any treatment. The treatments were well tolerated, without major adverse effects. Conclusions Sildenafil caused a long-lasting reduction in mean PAP and pulmonary vascular resistance, with a further additional improvement after iloprost inhalation. These data suggest that small doses of a phosphodiesterase type 5 inhibitor may be a useful adjunct to inhaled iloprost in the management of pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Primary Pulmonary Hypertension: A National Prospective Study
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,039
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,550
Primary pulmonary hypertension: natural history and the importance of thrombosis.
Fuster, V, Steele, P. M., Edwards, W. D., Gersh, B. J., McGoon, M. D., & Frye, R. L. (1984) · Circulation · doi:10.1161/01.cir.70.4.580 · Cited by 1,066
Hoeper, M. M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., Niedermeyer, J., Hamm, M., & Fabel, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422503 · Cited by 572
Effects of sildenafil citrate on human hemodynamics
Jackson, G., Benjamin, N., Jackson, N., & Allen, M. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00043-0 · Cited by 368
Sildenafil in Primary Pulmonary Hypertension
Prasad, S., Wilkinson, J., & Gatzoulis, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431814 · Cited by 337
Hoeper, M. M., Olschewski, H., Ghofrani, H. A., Wilkens, H., Winkler, J., Borst, M. M., Niedermeyer, J., Fabel, H., & Seeger, W. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00494-5 · Cited by 313
Self-citationInhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
Olschewski, H., Ghofrani, H. A., Schmehl, T., Winkler, J., Wilkens, H., Hoeper, M. M., Behr, J., Kleber, F. X., Seeger, W., & for the German PPH Study Group* (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00003 · Cited by 286
Self-citationSildenafil Is a Pulmonary Vasodilator in Awake Lambs with Acute Pulmonary Hypertension
Weimann, J., Ullrich, R., Hromi, J., Fujino, Y., Clark, M. W. H., Bloch, K. D., & Zapol, W. M. (2000) · Anesthesiology · doi:10.1097/00000542-200006000-00030 · Cited by 221
Cited by
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Medical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Metadata
- Authors
- Wilkens, H., Guth, A., König, J., Forestier, N., Cremers, B., Hennen, B., Böhm, M., & Sybrecht, G. W.
- Venue
- Circulation
- Published
- 2001-09-11
- Volume
- 104
- Issue
- 11
- Pages
- 1218-1222
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2153625446
- Cited by
- 392
- References
- 13
- FWCI
- 32.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension. https://app.cochat.ai/papers/10.1161/hc3601.096826
- The paper
- Wilkens, H., Guth, A., König, J., Forestier, N., Cremers, B., Hennen, B., Böhm, M., & Sybrecht, G. W. (2001). Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension. Circulation. https://doi.org/10.1161/hc3601.096826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.